These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 29987143)
41. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Moreno M; D'ávila DA; Silva MN; Galvão LM; Macedo AM; Chiari E; Gontijo ED; Zingales B Mem Inst Oswaldo Cruz; 2010 Nov; 105(7):918-24. PubMed ID: 21120364 [TBL] [Abstract][Full Text] [Related]
42. Sesquiterpene lactone potentiates the immunomodulatory, antiparasitic and cardioprotective effects on anti-Trypanosoma cruzi specific chemotherapy. Gonçalves-Santos E; Vilas-Boas DF; Diniz LF; Veloso MP; Mazzeti AL; Rodrigues MR; Oliveira CM; Fernandes VHC; Novaes RD; Chagas-Paula DA; Caldas IS Int Immunopharmacol; 2019 Dec; 77():105961. PubMed ID: 31685438 [TBL] [Abstract][Full Text] [Related]
43. The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance. Almeida-Silva J; Menezes DS; Fernandes JMP; Almeida MC; Vasco-Dos-Santos DR; Saraiva RM; Viçosa AL; Perez SAC; Andrade SG; Suarez-Fontes AM; Vannier-Santos MA Front Cell Infect Microbiol; 2022; 12():926699. PubMed ID: 35967878 [TBL] [Abstract][Full Text] [Related]
44. Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases Typical Cardiac Lesions in the Chronic Phase. Pereira RS; Malvezi AD; Lovo-Martins MI; Lucchetti BFC; Santos JP; Tavares ER; Verri WA; de Almeida Araújo EJ; Yamauchi LM; Yamada-Ogatta SF; Martins-Pinge MC; Pinge-Filho P Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366719 [TBL] [Abstract][Full Text] [Related]
45. Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. Francisco AF; de Abreu Vieira PM; Arantes JM; Pedrosa ML; Martins HR; Silva M; Veloso VM; de Lana M; Bahia MT; Tafuri WL; Carneiro CM Exp Parasitol; 2008 Dec; 120(4):314-9. PubMed ID: 18789321 [TBL] [Abstract][Full Text] [Related]
46. The immunomodulatory effects of the Enalapril in combination with Benznidazole during acute and chronic phases of the experimental infection with Trypanosoma cruzi. Leite ALJ; Paula Costa G; Lopes LR; Reis Mota LWD; Vieira PMA; Talvani A Acta Trop; 2017 Oct; 174():136-145. PubMed ID: 28720491 [TBL] [Abstract][Full Text] [Related]
47. 4-nitrobenzoylcoumarin potentiates the antiparasitic, anti-inflammatory and cardioprotective effects of benznidazole in a murine model of acute Trypanosoma cruzi infection. Vilas-Boas DF; Oliveira RRG; Gonçalves-Santos E; Silva LS; Diniz LF; Mazzeti AL; Brancaglion GA; Carvalho DT; Caldas S; Novaes RD; Caldas IS Acta Trop; 2022 Apr; 228():106314. PubMed ID: 35038424 [TBL] [Abstract][Full Text] [Related]
48. Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection. Santos DM; Martins TA; Caldas IS; Diniz LF; Machado-Coelho GL; Carneiro CM; Oliveira Rde P; Talvani A; Lana M; Bahia MT Acta Trop; 2010 Feb; 113(2):134-8. PubMed ID: 19854145 [TBL] [Abstract][Full Text] [Related]
49. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase. Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582 [TBL] [Abstract][Full Text] [Related]
50. Activity profile of two 5-nitroindazole derivatives over the moderately drug-resistant Fonseca-Berzal C; da Silva CF; Batista DDGJ; de Oliveira GM; Cumella J; Batista MM; Peres RB; Silva da Gama Nefertiti A; Escario JA; Gómez-Barrio A; Arán VJ; Soeiro MNC Parasitology; 2020 Sep; 147(11):1216-1228. PubMed ID: 32530391 [TBL] [Abstract][Full Text] [Related]